Journal: Oncotarget

Article Title: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II

doi: 10.18632/oncotarget.27585

Figure Lengend Snippet: A panel of approximately 300 hybridoma supernatants were generated and screened for specificity against rhAMHR2-ED and the 4D12 parental hybridoma was selected for subcloning by limiting dilution. ( A ) Subcloning produced three sub-clones, 4D12C6, 4D12C7, and 4D12G1 each of which expressed the IgG 1 /κ-chain isotype and showed antigen specificity ( B ) by competitive ELISA and ( C ) by flow cytometry binding to OVCAR8 cells. For flow cytometry, positive control staining of OVCAR8 cells was performed using a commercially available anti-AMHR2-ED mAb (Abcam), whereas IgG1 isotype antibodies with irrelevant specificities were used as negative controls. In all cases, error bars indicate ± SD and the results shown are representative of three experiments yielding similar results.

Article Snippet: The AMHR2-OVCAR8 cell line was generated by cloning transcript variant 1 of human AMHR2 (Accession #NM_020547; Origene, Rockville, MD) into pEZ-M68 vector (GeneCopoeia, Rockville, MD) and using this expression vector to transfect OVCAR8 cells using Lipofectamine™ 3000 (Thermo Fisher).

Techniques: Generated, Subcloning, Produced, Clone Assay, Competitive ELISA, Flow Cytometry, Binding Assay, Positive Control, Staining

Journal: Oncotarget

Article Title: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II

doi: 10.18632/oncotarget.27585

Figure Lengend Snippet: ( A ) Flow cytometry analysis showing that the 4D12G1 mAb binds to the majority of cells generated from two primary HGSOC tissues examined. Error bars indicate ± SD. ( B ) The 4D12G1 mAb was used in Western blots of seven different HGSOC tissue lysates (25 μg protein/lane) with a positive control lysate generated from a young C57BL/6 ovary and a negative control lysate generated from C4-2 human prostate cancer cells. Immunostaining with a β-actin antibody was used to confirm normalized lysate loading. The Western blots shown are representative of three experiments that provided similar results. ( C ) The 4D12G1 mAb was used in immunohistochemical staining (20 ×) of tissue sections from four HGSOC patients (left column) and their normal adjacent fallopian tube tissues (right column). Arrows indicate staining of the tumor parenchyma. The stromal areas of the EOC tumors were not immunostained nor were all areas of the normal adjacent fallopian tube tissues. All experiments were performed three times yielding similar results. ( D ) Western blot analysis of lysates from OVCAR8 cells and AMHR2-OVCAR8 cells with lysates from C4-2 prostate cancer cells used as controls and immunostaining with a β-actin antibody was used to confirm normalized lysate loading. Flow cytometry analysis showed that: ( E ) the 4D12G1 mAb binds to 91% of AMHR2-OVCAR8 cells; ( F ) the AMH cognate ligand for AMHR2-ED effectively competes in a dose-dependent manner with the 4D12G1 mAb for binding to AMHR2-OVCAR8 cells; and ( G ) recombinant ovalbumin failed to compete with the 4D12G1 mAb for binding to AMHR2-OVCAR8 cells. Data are representative of three independent experiments yielding similar results.

Article Snippet: The AMHR2-OVCAR8 cell line was generated by cloning transcript variant 1 of human AMHR2 (Accession #NM_020547; Origene, Rockville, MD) into pEZ-M68 vector (GeneCopoeia, Rockville, MD) and using this expression vector to transfect OVCAR8 cells using Lipofectamine™ 3000 (Thermo Fisher).

Techniques: Flow Cytometry, Generated, Western Blot, Positive Control, Negative Control, Immunostaining, Immunohistochemical staining, Staining, Binding Assay, Recombinant

Journal: Oncotarget

Article Title: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II

doi: 10.18632/oncotarget.27585

Figure Lengend Snippet: Details of EOC patients and their examined tumors

Article Snippet: The AMHR2-OVCAR8 cell line was generated by cloning transcript variant 1 of human AMHR2 (Accession #NM_020547; Origene, Rockville, MD) into pEZ-M68 vector (GeneCopoeia, Rockville, MD) and using this expression vector to transfect OVCAR8 cells using Lipofectamine™ 3000 (Thermo Fisher).

Techniques: Immunohistochemical staining, Expressing

Journal: Oncotarget

Article Title: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II

doi: 10.18632/oncotarget.27585

Figure Lengend Snippet: ( A ) The entire 132 amino acid sequence of human AMHR2-ED. ( B ) An overlapping series of 16-mer peptides spanning the entire sequence of human AMHR2-ED with one amino acid shifts were plated for direct ELISA testing using the 4D12G1 mAb as the primary antibody. The 4D12G1 mAb recognized residues AMHR2-ED 11–32. ( C ) Overlapping peptides spanning AMHR2-ED 13–30 were synthesized with alanine substitutions at each N-terminal residue or with glycine substitutions for any native N-terminal alanine residues. Competitive ELISA results showed that alanine substitutions at residues spanning AMHR2-ED 20-26 ( 20 KTLGELL 26 ) decreased binding of the 4D12G1 mAb to AMHR2-ED. ( D ) SPOT peptide arrays using 4-16-mer peptides spanning AMHR2-ED 9-40 were immobilized on cellulose membranes, treated with the 4D12G1 mAb, and the bound antibody was detected by chemiluminescence. The results showed that the AMHR2-ED 22–26 5-mer sequence ( 22 LGELL 26 ) represents the minimal sequence for binding of the 4D12G1 mAb. ( E ) SPOT peptide arrays were made using membrane bound 17-mer peptides spanning the AMHR2-ED 17–33 domain and containing alanine substitutions at each sequential amino acid. Alanine replacement of Leu 22 , Gly 23 , and Leu 26 completely abolished binding by the 4D12G1 mAb. All error bars indicate ±SD, and all experiments are representative of three experiments yielding similar data.

Article Snippet: The AMHR2-OVCAR8 cell line was generated by cloning transcript variant 1 of human AMHR2 (Accession #NM_020547; Origene, Rockville, MD) into pEZ-M68 vector (GeneCopoeia, Rockville, MD) and using this expression vector to transfect OVCAR8 cells using Lipofectamine™ 3000 (Thermo Fisher).

Techniques: Sequencing, Direct ELISA, Synthesized, Competitive ELISA, Binding Assay

Journal: Oncotarget

Article Title: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II

doi: 10.18632/oncotarget.27585

Figure Lengend Snippet: ( A ) AMHR2-OVCAR8 cells were treated with a green fluorescent dye and the 4D12G1 mAb or an isotype control mAb. Apoptosis was assessed by live imaging using the IncuCyte S3 analyzer. 4D12G1 mAb induced substantial apoptosis at 16 hours (right panel) compared to isotype control mAb (left panel). ( B ) AMHR2-OVCAR8 cells were treated with different concentrations of the 4D12G1 mAb for 24 hours and Western blots of the cell lysates showed detection of the intact 116 kDa PARP-1 and its 89 kDa cleaved variant, consistent with apoptosis. Immunostaining with a β-actin antibody was used to confirm normalized lysate loading. ( C ) AMHR2-OVCAR8 cells were incubated with the 4D12G1 mAb for different time periods at either 37° C (left column) or 4° C (right column). Clustered patterns of cytoplasmic antibody-receptor complexes became increasingly more prominent at 2 and 3 hours after treatment at 37° C, but not at 4° C, and no staining occurred in cells treated with secondary antibody alone (right column, bottom panel). ( D ) AMHR2-OVCAR8 cells were incubated in either 10% normal human serum or 10% heat-inactivated human serum and treated for 4 hours with varying doses of either 4D12G1 mAb or isotype control mAb. Cell lysis mediated by CDC was measured by release of LDH activity and occurred only in cells treated with the 4D12G1 mAb. ( E ) AMHR2-OVCAR8 target cells were labeled with a green fluorescent dye and incubated with two different concentrations of 4D12G1 mAb or isotype control mAb. The cells were mixed with effector macrophages from C57BL/6 mouse bone marrow at an effector to target cell ratio of 10:1. Live target cells were analyzed by flow cytometry 3 days later for demonstrating ADCP. All error bars indicate ±SD. All experiments are representative of three experiments yielding similar data.

Article Snippet: The AMHR2-OVCAR8 cell line was generated by cloning transcript variant 1 of human AMHR2 (Accession #NM_020547; Origene, Rockville, MD) into pEZ-M68 vector (GeneCopoeia, Rockville, MD) and using this expression vector to transfect OVCAR8 cells using Lipofectamine™ 3000 (Thermo Fisher).

Techniques: Imaging, Western Blot, Variant Assay, Immunostaining, Incubation, Staining, Lysis, Activity Assay, Labeling, Flow Cytometry

Journal: Oncotarget

Article Title: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II

doi: 10.18632/oncotarget.27585

Figure Lengend Snippet: Human EOC tumors were injected s. c. into immunodeficient mice. When tumors became palpable, mice were injected i. p. with 200 μg of either the 4D12G1 mAb or an isotype control mAb weekly for 5 continuous weeks. Treatment with the 4D12G1 mAb significantly inhibited the growth of OVCAR8 tumors in ( A ) severely immunodeficient NSG mice ( P < 0.001) and in ( B ) T cell-deficient athymic nude mice ( P < 0.0001). More importantly, treatment with the 4D12G1 mAb significantly inhibited the growth of three primary HGSOC tumors ( P < 0.0001 in all cases) generated from recently diagnosed patients and xenografted into immunodeficient NSG mice including ( C ) PDX-4, ( D ) PDX-6, and ( E ) PDX-9. ( F ) Detection of caspase-3 positive cells in the OVCAR8 (upper row) and PDX-4 tumors (lower row) from NSG mice at 20× is shown by arrows in mice treated with the 4D12G1 mAb (right column) compared to mice treated with isotype control mAb (left column). Caspase-3 data shown are representative of three experiments yielding similar results. All error bars indicate ± SD.

Article Snippet: The AMHR2-OVCAR8 cell line was generated by cloning transcript variant 1 of human AMHR2 (Accession #NM_020547; Origene, Rockville, MD) into pEZ-M68 vector (GeneCopoeia, Rockville, MD) and using this expression vector to transfect OVCAR8 cells using Lipofectamine™ 3000 (Thermo Fisher).

Techniques: Injection, Generated

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: Overexpression of lncRNA LINC00857 in ovarian cancer cells and tissues. ( A ) Relative expression levels of LINC00857 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) Relative expression levels of LINC00857 in OC cell line OVCAR8 compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. OC, ovarian cancer.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Over Expression, Expressing, Quantitative RT-PCR

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 enhances the invasion, migration, proliferation, and stemness of ovarian cancer cell OVCAR8. ( A ) qRT-PCR analysis of LINC00857 expression levels in OVCAR8 cells transfected with si-NC, si-LINC00857, the vector group, or a LINC00857 overexpression plasmid. ( B ) Cell viability was assessed using CCK-8 assay. ( C ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( D ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( E ) Representative images of sphere-formation assay showing the sphere-forming capacity of OVCAR8 cells in each group (scale bar = 50 μm). ( F–G ) The protein levels of SOX2, NANOG, and Oct4 in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Migration, Quantitative RT-PCR, Expressing, Transfection, Plasmid Preparation, Over Expression, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Tube Formation Assay, Cell Counting, Binding Assay

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 participates in the activation of YAP1. ( A ) Correlation analysis between LINC00857 and YAP1 expression based on TCGA database ( n = 353). ( B ) Immunohistochemistry analysis of YAP1 levels in OC tissues compared to adjacent tissues (scale bar = 20 μm); ** p < 0.01. ( C ) Western blot analysis of YAP1 protein expression levels in IOSE80 and OVCAR8 cells; ** p < 0.01. ( D ) Western blot analysis of YAP1, p-YAP1, LATS1, p-LATS1, and TEAD4 protein levels in OVCAR8 cells across groups. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. si-NC; ## p < 0.01 vs. Vector; statistical analysis was performed using unpaired two-tailed Student’s t-test (for two-group comparisons) or one-way ANOVA followed by Tukey’s post hoc test (for multiple comparisons). YAP1, yes-associated protein 1; TCGA, The Cancer Genome Atlas; OC, ovarian cancer; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; p-LATS1, phosphorylated-LATS1; TEAD4, TEA domain transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Activation Assay, Expressing, Immunohistochemistry, Western Blot, Plasmid Preparation, Two Tailed Test

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: METTL3 highly expresses in ovarian cancer cells and promotes the LINC00857 expression by m6A modification. ( A ) Relative expression levels of METTL3 in OC tissues compared to adjacent normal tissues using qRT-PCR ( n = 50). ( B ) The correlation between LINC00857 and METTL3 expression analyzed by Pearson ( n = 108). ( C ) Relative expression levels of METTL3 in OC cell line OVCAR8 compared to normal ovarian epithelial cell line IOSE80 using qRT-PCR ( n = 25). ( D ) The m6A enrichment levels of LINC00857 in IOSE80 and OVCAR8 cells were measured using the MeRIP-qPCR kit ( n = 25). ( E ) Relative METTL3 mRNA expression levels in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). ( F ) Western blot analysis showing METTL3 protein expression in OVCAR8 cells transfected with si-NC or si-METTL3 ( n = 3). ( G ) Relative mRNA expression of LINC00857 in OVCAR8 cells after METTL3 knockdown (si-METTL3) compared to the si-NC group ( n = 5). ( H ) m6A enrichment levels of LINC00857 in OVCAR8 cells transfected with si-METTL3 or si-NC using MeRIP-qPCR ( n = 5). ( I ) RNA pull-down assay showing the binding interaction between LINC00857 and METTL3 ( n = 5). ( J ) RNA stability assay indicating the relative expression of LINC00857 over time in OVCAR8 cells transfected with si-METTL3 or si-NC ( n = 5). Data were presented as mean ± SD; ** p < 0.01; statistical significance was determined using unpaired Student’s t-test. METTL3, methyltransferase-like 3; OC, ovarian cancer; m6A, N6-methyladenosine.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Expressing, Modification, Quantitative RT-PCR, Transfection, Western Blot, Knockdown, Pull Down Assay, Binding Assay, Stability Assay

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 reverses the migration, invasion, proliferation, and stemness of OVCAR8 cells inhibited by METTL3 down-regulation. ( A ) Cell viability of OVCAR8 cells was assessed using CCK-8 assay. ( B ) Cell invasion was evaluated using Transwell assay (scale bar = 50 μm). ( C ) Cell migration was measured using scratch assay (scale bar = 100 μm). ( D ) Representative images of sphere-formation assays showing the sphere-forming capability of OVCAR8 cells in each group (scale bar = 50 μm). ( E–F ) Western blot analysis showing the protein levels of SOX2, Oct4, and NANOG in OVCAR8 cells. Data were presented as mean ± SD ( n = 3 ~ 5); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; CCK-8, Cell Counting Kit-8; SOX2, SRY-box transcription factor 2; NANOG, Nanog homeobox; Oct4, octamer-binding transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Migration, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Western Blot, Cell Counting, Binding Assay

Journal: Scientific Reports

Article Title: METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway

doi: 10.1038/s41598-025-24958-w

Figure Lengend Snippet: LINC00857 reverses the effect of down-regulation of METTL3 on YAP1. ( A ) Representative protein bands of YAP1, p-YAP1, LATS1 and TEAD4 in OVCAR8 cells across groups. ( B ) Quantification of protein expression levels normalized to GAPDH. Data were presented as mean ± SD ( n = 3); ** p < 0.01 vs. NC; ## p < 0.01 vs. si-METTL3; statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. METTL3, methyltransferase-like 3; YAP1, yes-associated protein 1; p-YAP1, phosphorylated-YAP1; LATS1, large tumor suppressor 1; TEAD4, TEA domain transcription factor 4.

Article Snippet: OC cells (OVCAR8) were provided by Procell Life Science&Technology Co., Ltd (CL-0178, China).

Techniques: Expressing